To conclude, we have shown that CYP2C19 polymorphisms have no or little impact on concentration levels and MRs of tamoxifen, endoxifen, 4-hydroxy-tamoxifen and NDM-tamoxifen, or clinical outcomes in breast cancer patients. This evidence concerns the gene CYP2C19 and breast cancer.